Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 17;11(10):1607.
doi: 10.3390/vaccines11101607.

Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis

Brenda L Coleman  1   2   3 , Iris Gutmanis  1   3 , Ian McGovern  4 , Mendel Haag  5
Affiliations
Review

Effectiveness of Cell-Based Quadrivalent Seasonal Influenza Vaccine: A Systematic Review and Meta-Analysis

Brenda L Coleman et al. Vaccines (Basel). .

Abstract

Cell-based seasonal influenza vaccine viruses may more closely match recommended vaccine strains than egg-based options. We sought to evaluate the effectiveness of seasonal cell-based quadrivalent influenza vaccine (QIVc), as reported in the published literature. A systematic literature review was conducted (PROSPERO CRD42020160851) to identify publications reporting on the effectiveness of QIVc in persons aged ≥6 months relative to no vaccination or to standard-dose, egg-based quadrivalent or trivalent influenza vaccines (QIVe/TIVe). Publications from between 1 January 2016 and 25 February 2022 were considered. The review identified 18 relevant publications spanning three influenza seasons from the 2017-2020 period, with an overall pooled relative vaccine effectiveness (rVE) of 8.4% (95% CI, 6.5-10.2%) for QIVc vs. QIVe/TIVe. Among persons aged 4-64 years, the pooled rVE was 16.2% (95% CI, 7.6-24.8%) for 2017-2018, 6.1% (4.9-7.3%) for 2018-2019, and 10.1% (6.3-14.0%) for 2019-2020. For adults aged ≥65 years, the pooled rVE was 9.9% (95% CI, 6.9-12.9%) in the egg-adapted 2017-2018 season, whereas there was no significant difference in 2018-2019. For persons aged 4-64 years, QIVc was consistently more effective than QIVe/TIVe over the three influenza seasons. For persons aged ≥65 years, protection with QIVc was greater than QIVe or TIVe during the 2017-2018 season and comparable in 2018-2019.

Keywords: cell-based; influenza; quadrivalent influenza vaccine; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

I.M. and M.H. are employed by CSL Seqirus Inc. B.L.C. and I.G. report receipt of funding to their institution (Sinai Health) from CSL Seqirus Inc.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) flow sheet detailing study selection.
Figure 2
Figure 2
Forest plot of rVE estimates of QIVc compared with QIVe (or QIVe/TIVe) in preventing medical encounters for persons aged 4–64 years, 2017–2018 to 2019–2020. Pooled rVE estimates were calculated separately for each season. adm, admission; CI, confidence interval; ED, emergency department; hosp; hospital; I sq, I2 (heterogeneity measure); Outpt, outpatient; QIVc, cell-based quadrivalent inactivated influenza vaccine; QIVe, egg-based quadrivalent inactivated influenza vaccine; rVE, relative vaccine effectiveness; TIVe, egg-based trivalent influenza vaccine [24,25,26,29,30,31,32,33,34,35,36].
Figure 3
Figure 3
Forest plot of rVE estimates of QIVc compared with QIVe (or QIVe/TIVe) in preventing medical encounters for adults ≥65 years of age, by season, 2017–2018 and 2018–2019. Pooled rVE estimates were calculated separately for each season. adm, admission; ED, emergency department; Hosp, hospital; I sq, I2 (heterogeneity measure); Outpt, outpatient; QIVc, cell-based quadrivalent inactivated influenza vaccine; QIVe, egg-based quadrivalent inactivated influenza vaccine; rVE, relative vaccine effectiveness; TIVe, egg-based trivalent inactivated influenza vaccine [24,25,29,30,31,37].
See this image and copyright information in PMC

References

    1. Rajaram S., Boikos C., Gelone D.K., Gandhi A. Influenza vaccines: The potential benefits of cell-culture isolation and manufacturing. Ther. Adv. Vaccines Immunother. 2020;8:2515135520908121. doi: 10.1177/2515135520908121. - DOI - PMC - PubMed
    1. Zost S.J., Parkhouse K., Gumina M.E., Kim K., Diaz Perez S., Wilson P.C., Treanor J.J., Sant A.J., Cobey S., Hensley S.E. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA. 2017;114:12578–12583. doi: 10.1073/pnas.1712377114. - DOI - PMC - PubMed
    1. de Lejarazu-Leonardo O.R., Montomoli E., Wojcik R., Christopher S., Mosnier A., Pariani E., Trilla Garcia A., Fickenscher H., Gärtner B.C., Jandhyala R., et al. Estimation of reduction in influenza vaccine effectiveness due to egg-adaptation changes—Systematic literature review and expert consensus. Vaccines. 2021;9:1255. doi: 10.3390/vaccines9111255. - DOI - PMC - PubMed
    1. World Health Organization Cell culture as a substrate for the production of influenza vaccines: Memorandum from a WHO meeting. Bull. World Health Organ. 1995;73:431–435. - PMC - PubMed
    1. Chen J.R., Liu Y.M., Tseng Y.C., Ma C. Better influenza vaccines: An industry perspective. J. Biomed. Sci. 2020;27:33. doi: 10.1186/s12929-020-0626-6. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources